CDXS - Codexis Inc Growth-Adjusted P/E Ratio
The patent-protected DNA engineering sector creates high barriers to entry for competitors, which is confirmed by the P/E ratio relative to the projected EPS growth for Codexis, Inc. (CDXS). The current level of this metric is 0.00, illustrating management efficiency. The trust of pharma behemoths is based on the CodeEvolver AI system, while the strategic vector is shifting toward licensing high-margin enzymatic synthesis for global corporations.
Analytical breakdowns for Codexis, Inc. (CDXS)
- current quotes and average value forecast:
- market capitalization statistics:
- business book valuation details:
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Codexis, Inc.|CDXS - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient codexis.com|CDXS - Company Debts|Debt to Book Value Ratio Codexis Bio|CDXS - Company Long-Term Debts|Company Current Liabilities Codexis, Inc.|Interim Coverage Ratio codexis.com
- net income and valuation ratios data:
CDXS - Net Profit|Future Profit Codexis, Inc.|CDXS - P/E Multiple|Price to Future Earnings Ratio codexis.com|CDXS - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Codexis Bio|CDXS - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Codexis, Inc.|CDXS - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months codexis.com|CDXS - Earnings per share growth in current year|Projected earnings per share growth rate for next year Codexis, Inc.
Fundamental company analysis:Codexis Inc (CDXS)
The PEG ratio compares the market value of earnings to their growth rate, where a value below one signals that an asset is undervalued relative to its expansion. By analyzing PEG ratio dynamics, an investor determines the balance between price and revenue growth speed, which for Codexis, Inc. (CDXS) confirms the effectiveness of diversifying enzyme developments across pharmaceuticals and ecology.
Competing companies
TEM - Price to Earnings Adjusted for Growth Rate|Qiagen Group - Price/Earnings to Growth Multiple|IONS: Growth-Adjusted P/E Ratio|Repligen Corporation - PEG Multiple|Growth-Adjusted Market Cap to Net Income aviditybiosciences.com RNA|CRISPR Therapeutics (CRSP) - Price/Earnings to Growth Ratio|WGS - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple RARE|BEAM: Growth-Adjusted Payback Ratio|PEG Multiple SRPT|Growth-Adjusted Market Cap to Net Income twistbioscience.com|Price/Earnings to Growth Ratio 10x Genomics TXG|NTLA: Growth-Adjusted P/E Ratio|Stoke - PEG Multiple|BioLife (BLFS) - Price/Earnings to Growth Multiple|WVE (Wave Life Sciences) - Price/Earnings to Growth Multiple|MAZE - Growth-Adjusted Market Cap to Net Income|SION (Sionna Therapeutics) - PEG Multiple|Price/Earnings to Growth Multiple Prime Medicine Inc (PRME)|PEG Multiple TSHA|uniQure Pharma - Growth-Adjusted P/E Ratio|MeiraGTx Holdings plc - Price/Earnings to Growth Multiple|RGNX: Growth-Adjusted P/E Ratio|SLDB - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income Ocugen Inc OCGN|PACB: PEG Multiple|Growth-Adjusted P/E Ratio BNTC|Price/Earnings to Growth Ratio Design Therapeutics|Growth-Adjusted P/E Ratio RCKT (rocketpharma.com)|PEG Multiple FDMT|PEG Multiple lexeotx.com (LXEO)|PEG Multiple KRRO (Korro Bio)|EDIT - Price/Earnings to Growth Multiple|SLN - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate ProQR Therapeutics N.V.|SGMO: PEG Multiple|Growth-Adjusted P/E Ratio NAUT|MGX (Metagenomi, Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Precision BioSciences Inc. DTIL|Price/Earnings to Growth Multiple GBIO (Generation Bio Co.)|boundlessbio.com - Growth-Adjusted P/E Ratio|PEG Multiple XCUR (Exicure)|Growth-Adjusted Market Cap to Net Income Imunon Inc (IMNN)|PHIO - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income Mustang Bio, Inc. MBIO|RNAZ (transcodetherapeutics.com) - Price/Earnings to Growth Multiple|Bionano Genomics - Growth-Adjusted Payback Ratio|APDN (Applied DNA Sciences, Inc.) - PEG Multiple|bluebird bio Inc. (BLUE) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio ImmunoPrecise Antibodies (IPA)|Omega Therapeutics Corp - Growth-Adjusted P/E Ratio|PEG Multiple OMIC (Singular Genomics Systems)|RGLS - Price/Earnings to Growth Multiple|SYRS: Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income Telesis Bio Inc. TBIO|TCON: PEG Multiple|Price/Earnings to Growth Multiple Unity Biotechnology, Inc
